Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide Monotherapy in Drug-Naive Type 2 Diabetes
NCT00381342Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2006
- Primary completion
- Sep 2007
- Modality
- Peptides
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of exenatide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by AstraZeneca. Primary endpoint: Change in HbA1c (glycosylated hemoglobin) at 24 weeks. Started Sep 2006; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00381342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00381342.